[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641930":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":11,"centralContacts":35,"locations":42,"responsibleParty":55,"collaborators":11,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":11,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":11,"enrollmentInfo":66,"targetDuration":11,"studyType":69,"phases":70,"briefSummary":73,"conditions":74,"keywords":11,"overallStatus":76,"whyStopped":11,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Shanghai Helioson Pharmaceutical Co., Ltd.","INDUSTRY",[8,14,17,20,23,26],{"label":9,"type":10,"description":11,"interventionNames":12},"escalation part","EXPERIMENTAL",null,[13],"Drug: HP-002",{"label":15,"type":10,"description":11,"interventionNames":16},"expansion cohort 1",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"expansion cohort 2",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"expansion cohort 3",[13],{"label":24,"type":10,"description":11,"interventionNames":25},"expansion cohort 4",[13],{"label":27,"type":10,"description":11,"interventionNames":28},"expansion cohort 5",[13],[30],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":11},"DRUG","HP-002","HP-002 will be taken once daily, at approximately the same time each morning.",[9,15,18,21,24,27],[36],{"name":37,"role":38,"phone":39,"phoneExt":40,"email":41},"Yunju Yi","CONTACT","+86","+8613518115493","yiyunju@eastonpharma.cn",[43],{"facility":44,"status":11,"city":45,"state":46,"zip":11,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":11},"Sun Yat-sen University Cancer Center","Guangzhou","Guangdong","China","CN",{"type":50,"coordinates":51},"Point",[52,53],113.25,23.11667,{"lat":53,"lon":52},{"type":56,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100641930","phase-1-a-first-in-human-study-of-hp-002-for-relapsed-or-refractory-b-cell-non-hodgkin-lymphoma-100641930",false,"NCT07658352","A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma","An Open-label, First-in-human Dose Escalation and Dose Expansion Phase I\u002FII Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HP-002 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group Performance Status (ECOG) of 0-2.\n* Patients with relapsed or refractory B-cell non-Hodgkin lymphoma subtypes (CLL\u002FSLL, MCL, MZL, DLBCL, FL, WM, and PCNSL).\n\nExclusion Criteria:\n\n* Prior use of a BTK protein degrader.","ALL","18 Years",{"count":67,"type":68},114,"ESTIMATED","INTERVENTIONAL",[71,72],"PHASE1","PHASE2","This is an open-label, first-in-human dose escalation and dose expansion Phase I\u002FII clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HP-002 in patients with relapsed or refractory B-Cell Non-Hodgkin Lymphoma This study consists of two phases: a dose-exploration phase and a dose-expansion phase.\n\nThe safety and tolerability of HP-002 will be evaluated in Phase 1 study, as well as the maximum tolerated dose (MTD) and the recommended dose level for Phase 2 study will be determined.\n\nThe efficacy of HP-002 will be evaluated in Phase 2 study.",[75],"B-Cell Non-Hodgkin Lymphoma","NOT_YET_RECRUITING","2026-06-16",{"date":79,"type":80},"2026-06-22","ACTUAL",{"date":82,"type":68},"2026-06-26",{"date":84,"type":68},"2031-06-26",{"name":5,"class":6},1]